Participant flow

Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation · Source last updated 2024-03-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant. Melphalan: Given IV Peripheral Blood Stem Cell Transplantation--CD34 HSCT: Undergo autologous CD34 HSCT Peripheral Blood Stem Cell Transplantation--AHSCT: Undergo AHSCT T Cell-Depleted Hematopoietic Stem Cell Transplantation: Undergo autologous CD34 HSCT Tetanus Toxoid Vaccine: Given IM

   id

   FG000

   title

   Arm I (Vaccine, CD34 Transplant, DLI)

2. description

   Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0. Melphalan: Given IV Peripheral Blood Stem Cell Transplantation--AHSCT: Undergo AHSCT Tetanus Toxoid Vaccine: Given IM

   id

   FG001

   title

   Arm II (Vaccine, Stem Cell Transplant)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         4

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         4

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice